Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results
Matthew J. Wieduwilt(Atrium Health Wake Forest Baptist), Richard M. Stone(Dana-Farber Cancer Institute), Scott Hall, James K. Mangan(UC San Diego Health System), Alice S. Mims(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Kimberley Doucette(Georgetown University), Carolin S. Escherich(St. Jude Children's Research Hospital), Jun J. Yang(St. Jude Children's Research Hospital), Kenneth Byrd(University of Kansas Medical Center), Shira Dinner(Dana-Farber Cancer Institute), Giorgia Giordano(University of Chicago), Mark R. Litzow(Mayo Clinic in Arizona), Rebecca Teske(Alliance Data (United States)), Zhenhua Li(St. Jude Children's Research Hospital), Geoffrey L. Uy(Memorial Sloan Kettering Cancer Center), Jun Yin(Mayo Clinic), Caner Saygin(University of Chicago), Ali W. Bseiso(University Hospitals of Cleveland), Wendy Stock(University of Chicago), Katarzyna Jamieson(University of North Carolina at Chapel Hill), Oudom Kour(Alliance Data (United States))
Cited by 7
Related Papers
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k